Influence of immune surveillance and immune privilege on formation of intraocular tumors

Chemical Immunology and Allergy

Volumn 92, Issue , 2007, Pages 276-289

  Chen, Peter W ^a   Ksander, Bruce R ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b SCHEPENS EYE RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DENDRITIC CELL; EFFECTOR CELL; HUMAN; IMMUNOSURVEILLANCE; INNATE IMMUNITY; INTRAOCULAR TUMOR; MACROPHAGE; MICROENVIRONMENT; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TUMOR CELL; TUMOR GROWTH; ANIMAL; EYE; EYE TUMOR; IMMUNOLOGY; PHYSIOLOGY; REVIEW; TUMOR ESCAPE;

GAMMA INTERFERON;

ANIMALS; EYE; EYE NEOPLASMS; HUMANS; IMMUNITY, NATURAL; INTERFERON TYPE II; KILLER CELLS, NATURAL; TUMOR ESCAPE;

EID: 33947500154     PISSN: 16602242     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000099278     Document Type: Article

References (41)

1. Ehrlich P: Ueber den jetzigen Stand der Karzinomforschung. Ned Tijdschr Geneeskd 1909;5: 273-290.
2. Thomas L: Reactions to homologous tissue antigens in relation to hypersensitivity; in Lawrence HS (ed): Cellular and Humoral Aspects of the Hypersensitive States. New York, Hoeber-Harper, 1959, pp 529-532.
3. Burnet FM: Immunological factors in the process of carcinogenesis. Br Med Bull 1964;20:154-158.
4. Old LJ, Boyse EA: Specific antigens of tumors and leukemias of experimental animals. Med Clin North Am 1966;50:901-912.
5. Klein G: Tumor antigens. Annu Rev Microbiol 1966;20:223-252.
6. Stutman O: Tumor development after 3-methylcholanthrene in immunologically deficient athymicnude mice. Science 1974;183:534-536.
7. Herberman RB, Holden HT: Natural cell-mediated immunity. Adv Cancer Res 1978;27:305-377.
8. Dighe AS, Richards E, Old LJ, Schreiber RD: Enhanced in vivo growth resistance to rejection of tumor cells expressing dominant negative IFNγ receptors. Immunity 1994;1:447-456.
9. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, Schreiber RD: Demonstration of an γ-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 1998;95:7556-7561.
10. Street SE, Trapani JA, MacGregor D, Smyth MJ: Suppression of lymphoma and epithelial malignancies effected by interferon γ. J Exp Med 1998;196:129-134.
11. van den Broek MF, Kagi D, Ossendorp F, Toes R, Vamvakas S, Lutza WK, Melief CJM, Zinkernagel RM, Hengartner H: Decreased tumor surveillance in perforin-deficient mice. J Exp Med 1996;184:1781-1790.
12. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD: IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001;410: 1107-1111.
13. Smyth MJ, Crowe NY, Godfrey DI: NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int Immunol 2001;13:459-463.
14. Girardi M, Oppenheim DE, Steele CR, Lewis JM, Glusac E, Filler R, Hobby P, Sutton B, Tigelaar RE, Hayday AC: Regulation of cutaneous malignancy by γδ T cells. Science 2001;294:605-609.
15. Nacht M, Jacks T: V(D)J recombination is not required for the development of lymphoma in p53-deficient mice. Cell Growth Differ 1998;9:131-138.
16. Liao MJ, Zhang XX, Hill R, Gao J, Qumsiyeh MB, Nichols W, Van Dyke T: No requirement for V(D)J recombination in p53-deficient thymic lymphoma. Mol Cell Biol 1998;18:3495-3501.
17. Diefenbach A, Raulet DH: Innate immune recognition by stimulatory immunoreceptors. Curr Opin Immunol 2003;15:37-44.
18. Brandlein S, Pohle T, Ruoff N, Wozniak E, Muller-Hermelink HK, Vollmers HP: Natural IgM anti-bodies and immunosurveillance mechanisms against epithelial cancer cells in humans. Cancer Res 2003;63:7995-8005.
19. Algarra I, Ohlen C, Perez M, Ljunggren HG, Klein G, Garrido F, Karre K: NK sensitivity and lung clearance of MHC-class-I-deficient cells within a heterogeneous fibrosarcoma. Int J Cancer 1989;44:675-680.
20. Vetter CS, Groh V, thorStraten P, Spies T, Brocker EB, Becker JC: Expression of stress-induced MHC class I related chain molecules on human melanoma. J Invest Dermatol 2002;118:600-605.
21. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T: Broad tumor-associated expression and recognition by tumor-derived γδ T cells of MICA and MICB. Proc Natl Acad Sci USA 1999;96:6879-6884.
22. Gilfillan S, Ho EL, Cella M, Yokoyama WM, Colonna M: NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation. Nat Immunol 2002;3:1150-1155.
23. Salih HRD Rammensee HG, Steinle A: Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol 2002;169:4098-4102.
24. Taniguchi M, SeBno K, Nakayama T: The NKT cell system: bridging innate and acquired immunity. Nat Immunol 2003;4:1164-1165.
25. Smyth MJ, Thia KY, Street SE, Cretney E, Trapani JA, Taniguchi M, Kawano T, Pelikan SB, Crowe NY, Godfrey DI: Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 2000;191:661-668.
26. Crowe NY, Coquet JM, Berzins SP, Kyparissoudis K, Keating R, Pellicci DG, Hayakawa Y, Godfrey DI, Smyth MJ: Differential antitumor immunity mediated by NKT cell subsets in vivo. J Exp Med 2005;202:1279-1288.
27. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD: Cancer immunoediting: from immuno-surveillance to tumor escape. Nat Immunol 2002;3:991-998.
28. Schreiber H, Wu TH, Nachman J, Kast WM: Immunodominance and tumor escape. Semin Cancer Biol 2002;12:25-31.
29. Matsui S, Ahlers JD, Vortmeyer AO, Terabe M, Tsukui T, Carbone DP, Liotta LA, Berzofsky JA: Amodel for CD8CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL. J Immunol 1999;163:184-193.
30. Dunn GP, Old LJ, Schreiber RD: The immunobiology of cancer immunosurveillance and immuno-editing. Immunity 2004;21:137-148.
31. Khong HT, Restifo NP: Natural selection of tumor variants in the generation of 'tumor escape' phenotypes. Nat Immunol 2002;3:999-1005.
32. O'Brien JM, Marcus DM, Bernards R, Carpenter JL, Windle JJ, Mellon PL, Albert DM: A transgenic mouse model for trilateral retinoblastoma. Arch Ophthalmol 1990;108:1145-1151.
33. Morilla-Grasa A: Animal modEls in uveal melanoma: establishment and research. Can J Ophthalmol 2004;39:433-440.
34. Mo JS, Anderson MG, Gregory M, Smith RS, Savinova OV, Serreze DV, Ksander BR, Streilein JW, John SWM: By altering ocular immune privilege, bone marrow-derived cells pathogenically contribute to DBA/2J pigmentary glaucoma. J Exp Med 2003;197:1335-1344.
35. Apte RS,RSinha D, Mayhew E, Wistow GJ, Niederkorn JY: Cutting edge: role of macrophage migration inhibitory factor in inhibiting NK cell activity and preserving immune privilege. J Immunol 1998;160:5693-5696.
36. Taylor AW: The immunomodulating neuropeptide alpha-melanocyte-stimulating hormone (α-MSH) suppresses LPS-stimulated TLR4 with IRAK-M in macrophages. J Neuroimmunol 2005;162: 43-50.
37. 2-treated antigen presenting cells. Invest Ophthalmol Vis Sci 2000;41:1410-1421.
38. Faunce DE, Stein-Streilein J: NKT cell-derived RANTES recruits APCs and CD8cells to the spleen during the generation of regulatory T cells in tolerance. J Immunol 2002;169:31-38.
39. Skelsey ME, Mellon J, Niederkorn JY: γδ T cells are needed for ocular immune privilege and corneal graft survival. J Immunol 2001;166:4327-4333.
40. Skelsey ME, Mayhew E, Niederkorn JY: CD25+, interleukin-10-producing CD4+ T cells are required for suppressor cell production and immune privilege in the anterior chamber of the eye. Immunology 2003;110:18-29.
41. Kezuka T, Streilein JW: In vitro generation of regulatory CD8+ cells similar to those found in mice with anterior chamber-associated immune deviation. Invest Ophthalmol Vis Sci 2000;41:1803-1811.